Drugs / LOP628
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02221505 | Dec 2014 → Mar 2015 | acute myeloid leukemia | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LOP628 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02221505 ↗ |
| Route | Intravenous | “Administered Intravenously” NCT02221505 ↗ |
| Target | KIT | “LOP628 provides an opportunity to target cKit overexpressing tumors.” NCT02221505 ↗ |